Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK‐positive non‐small cell lung cancer: A retrospective, real‐world study
Yang, Guangjian; Ma, Di; Xu, Haiyan; Yang, Lu; Li, Junling; Xing, Puyuan; Hao, Xuezhi; Wang, Yan
- 期刊名称Cancer Medicine
- 作者Yang, Guangjian; Ma, Di; Xu, Haiyan; Yang, Lu; Li, Junling; Xing, Puyuan; Hao, Xuezhi; Wang, Yan
- 印刷ISSN2045-7634
- 电子ISSN2045-7634
- 文件大小632.02KB
- 发表时间2019-08-13
- DOI10.1002/cam4.2420